Use of Razoxane for the Treatment of Alzheimer's Disease
Posted Aug 31 2008 5:00pm
Description of Invention: Abnormalities in the metabolism of the transition metals, iron and copper, have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Excessive iron accumulation in the brain occurs in both AD and PD. High levels of reactive iron can increase oxidative stress-induced neuronal vulnerability, increase the toxicity of environmental or endogenous toxins, and accelerate hallmark pathologies of these diseases.
As an example among many, the expression level of amyloid-beta precursor protein (APP) that generates the AD neurotoxic peptide, amyloid-beta (A-beta), is regulated in large part by iron levels. APP mRNA has an iron response element (IRE) in its 5'-untranslated region, and cleavage of APP to release different amyloidogenic and non-amyloidogenic peptide forms involves metalloproteases.
Elevated A-beta levels as well as plaques formed by aggregation of A-beta involve iron, and play a significant role in degeneration of the brain seen in AD. Chelators can reduce both the generation and aggregation of A-beta. Razoxane, a bisdioxopiperazine, is an orally active metal chelator approved for the treatment of cancer, where it and dexrazoxane have been effectively used for decades. In neuronal cell culture models, razoxane induced dose-dependent reductions in APP and A-beta levels without toxicity. In animal experiments (transgenic mice expressing human A-beta), razoxane substantially reduced A-beta 1-40 and 1-42 in brain by up to 46% without toxicity following once daily, 21 day administration.
The claimed invention is the novel use of razoxane and other bisdioxopiperazines to reduce amyloid-beta peptide levels, reduce aggregation of alpha-synuclein and tau protein, and reduce abnormal protein folding or aggregation for the treatment of AD and related diseases with protein aggregation pathology. Since razoxane has been approved for humans use, it could be more quickly developed as a treatment for AD, PD and other diseases.
Development Status: Clinical safety data and pre-clinical efficacy data for treatment of Alzheimer's disease.
Collaborative Research Opportunity: The National Institute on Aging, Laboratory of Neurosciences, Section on Drug Design & Development, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize razoxane and analogues for the treatment of neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. Please contact Nigel H. Greig ( firstname.lastname@example.org ) for more information.
Portfolios: Central Nervous System Central Nervous System - Therapeutics
For Additional Information Please Contact: Norbert Pontzer Ph.D., J.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 23, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5502 Fax: 301-402-0220